Alcolea Group discovery on tumour development could help catch and treat cancer at earliest stages
4 March 2026
Scientists from the Alcolea Group at the Cambridge Stem Cell Institute and collaborators at PDN have shown that when tumours first emerge, interactions with healthy cells in the underlying supportive tissue determine their ability to survive, grow, and progress to advanced stages of disease. The study, carried out in mice...
22 January 2026
The Hodson Group and collaborators have developed a customised blood test that can predict, more accurately than standard scans, whether treatment has successfully eradicated diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common form of aggressive non-Hodgkin lymphoma, and is typically treated with a combination...
13 January 2026
The collaboration, announced last month, will use state-of-the-art genomics approaches in combination with machine learning methods to advance our scientific understanding of cells and tissues in health and disease. GSK is investing nearly £10 million in this ground-breaking alliance that brings together the expertise of...
CSCI celebrates fourth annual Christmas Market at JCBC!
8 December 2025
On Friday 5 December, CSCI celebrated our fourth annual Christmas Market at the Jeffrey Cheah Biomedical Centre . Partnering with our neighbours at Cancer Research UK Cambridge Institute , Cambridge Biomedical Campus , The Milner Therapeutics Institute , and Cambridge Institute of Therapeutic Immunology & Infectious...
CSCI is a strategic collaboration between the University of Cambridge School of Biological Sciences and the School of Clinical Medicine.
If you'd like to make a donation to the Cambridge Stem Cell Institute, please email comms@stemcells.cam.ac.uk or donate using the button above.
Sign up to our newsletter to stay up to date with news and events from the Cambridge stem cell community.
You can also find us on
© 2026 University of Cambridge
